2018
Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D, Initiative T. Cognition among individuals along a spectrum of increased risk for Parkinson’s disease. PLOS ONE 2018, 13: e0201964. PMID: 30125297, PMCID: PMC6101368, DOI: 10.1371/journal.pone.0201964.Peer-Reviewed Original ResearchConceptsParkinson's diseaseIdiopathic REM sleep behavior disorderParkinson's Progression Markers Initiative (PPMI) studyDe novo Parkinson's diseaseREM sleep behavior disorderDopamine transporterNon-motor symptomsNovo Parkinson's diseaseSleep behavior disorderNon-motor featuresSymbol Digit Modalities TestBaseline neuropsychological performanceMontreal Cognitive AssessmentFuture neurodegenerationLewy bodiesInclusion criteriaSpectrum of riskMutation carriersInitiative studyCohortBehavior disorderCognitive functionCognitive test scoresModalities TestNeuropsychological performance
2017
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D, Initiative T. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLOS ONE 2017, 12: e0175674. PMID: 28520803, PMCID: PMC5435130, DOI: 10.1371/journal.pone.0175674.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBrain-Derived Neurotrophic FactorCatechol O-MethyltransferaseCognitive DysfunctionDiffusion Tensor ImagingDopamine Plasma Membrane Transport ProteinsFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedParkinson DiseasePolymorphism, Single NucleotideTau ProteinsTomography, Emission-Computed, Single-PhotonConceptsParkinson's diseaseCognitive impairmentDe novo Parkinson's diseaseDopamine transporter single-photon emissionLongitudinal mixed-effects modelsNovo Parkinson's diseaseYears of diseaseIdiopathic Parkinson's diseaseMovement Disorders CenterSingle nucleotide polymorphismsStructural magnetic resonance imagingClinical trial designLongitudinal structural MRIMagnetic resonance imagingSingle photon emissionDevelopment of treatmentsDiffusion tensor imagingBiomarker predictorsPlaque pathologyAmyloid pathologyDopamine deficiencyDopaminergic deficitUnivariate analysisBiomarker changesDisorders Center
2015
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub D, Simuni T, Caspell‐Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine M, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Initiative T. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders 2015, 30: 919-927. PMID: 25737166, PMCID: PMC4855523, DOI: 10.1002/mds.26170.Peer-Reviewed Original ResearchConceptsParkinson's Progression Markers InitiativeNeuropsychiatric symptomsPD patientsHealthy controlsProgression Markers InitiativeParkinson's diseaseCognitive impairmentUntreated PD patientsDopamine replacement therapySignificant depressive symptomsGroup differencesSymptoms of depressionQuality of lifeMild cognitive impairmentUntreated patientsDisease courseReplacement therapyICD symptomsControl disordersDepressive symptomsGeneral populationPatientsMeeting criteriaMulti-site studyBiological predictors
2011
The Parkinson Progression Marker Initiative (PPMI)
Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Klinik P, Sherer T, Frasier M, Meunier C, Rudolph A, Casaceli C, Seibyl J, Mendick S, Schuff N, Zhang Y, Toga A, Crawford K, Ansbach A, De Blasio P, Piovella M, Trojanowski J, Shaw L, Singleton A, Hawkins K, Eberling J, Brooks D, Russell D, Leary L, Factor S, Sommerfeld B, Hogarth P, Pighetti E, Williams K, Standaert D, Guthrie S, Hauser R, Delgado H, Jankovic J, Hunter C, Stern M, Tran B, Leverenz J, Baca M, Frank S, Thomas C, Richard I, Deeley C, Rees L, Sprenger F, Lang E, Shill H, Obradov S, Fernandez H, Winters A, Berg D, Gauss K, Galasko D, Fontaine D, Mari Z, Gerstenhaber M, Brooks D, Malloy S, Barone P, Longo K, Comery T, Ravina B, Grachev I, Gallagher K, Collins M, Widnell K, Ostrowizki S, Fontoura P, Ho T, Luthman J, van der Brug M, Reith A, Taylor P, Initiative T. The Parkinson Progression Marker Initiative (PPMI). Progress In Neurobiology 2011, 95: 629-635. PMID: 21930184, PMCID: PMC9014725, DOI: 10.1016/j.pneurobio.2011.09.005.Peer-Reviewed Original ResearchConceptsParkinson's Progression Markers InitiativeProgression Markers InitiativeProgression biomarkersCerebrospinal fluidMulti-center studyTherapeutic trialsPPMI cohortHealthy subjectsBiomarker assessmentClinical sitesStudy databaseReview CommitteeDisease etiologyLongitudinal collectionComprehensive observationalBiomarkersStudy dataAcquisition protocolsLikelihood of successEtiologyCohortBlood
2009
Endophenotypes in schizophrenia: A selective review
Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in schizophrenia: A selective review. Schizophrenia Research 2009, 109: 24-37. PMID: 19223268, PMCID: PMC2665704, DOI: 10.1016/j.schres.2009.01.016.Peer-Reviewed Original Research